Novo Nordisk profit flat; upbeat on sales outlook

Novo Nordisk profit flat; upbeat on sales outlook


Danish pharmaceutical company Novo Nordisk A/S on Wednesday reported flat second-quarter net profit, but lifted its growth targets for the year on expectations of robust sales of its type-2 diabetes drug Victoza and long-acting insulin Tresiba. Sales in the quarter got a boost from sales of new diabetes and obesity drugs, but growth in North America was pegged back by adjustments to rebates and competition from generic drugs.



from Biotech News